US 11,905,295 B2
Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders
Samuel Clark, New York, NY (US)
Assigned to Terran Biosciences Inc., New York, NY (US)
Filed by Terran Biosciences Inc., New York, NY (US)
Filed on Feb. 28, 2023, as Appl. No. 18/176,462.
Application 18/176,462 is a continuation of application No. 18/056,717, filed on Nov. 17, 2022.
Claims priority of provisional application 63/319,734, filed on Mar. 14, 2022.
Claims priority of provisional application 63/316,998, filed on Mar. 5, 2022.
Claims priority of provisional application 63/310,981, filed on Feb. 16, 2022.
Claims priority of provisional application 63/280,514, filed on Nov. 17, 2021.
Claims priority of provisional application 63/280,519, filed on Nov. 17, 2021.
Prior Publication US 2023/0279017 A1, Sep. 7, 2023
Int. Cl. A61K 31/551 (2006.01); C07D 487/14 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 28 Claims
 
1. A solid form of tabernanthalog monofumarate salt of the following formula:

OG Complex Work Unit Chemistry
wherein the solid form is crystalline polymorphic Pattern #6a;
(i) wherein crystalline polymorphic Pattern #6a is characterized by an X-ray powder diffraction diffractogram comprising two signals at angles (°2θ) selected from the group consisting of 19.6°±0.2 °2θ, 20.8°±0.2 °2θ, and 26.2°±0.2 °2θ; or
(ii) wherein crystalline polymorphic Pattern #6a is characterized by an X-ray powder diffraction diffractogram comprising three signals at angles (°2θ) selected from the group consisting of 16.2°±0.2 °2θ, 18.9°±0.2 °2θ, 20.2°±0.2 °2θ, and 24.9°±0.2 °2θ; and
wherein the X-ray powder diffraction diffractogram signals are present when the X-ray powder diffraction is carried out using Cu Kα1 radiation.
 
8. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the solid form of claim 1.